Announces that a Type C meeting with the U.S. Food and Drug Administration has resulted in alignment ...
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient...
Announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration on April 16, ...
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational,...
Announced the completion of the previously announced change in the jurisdiction of incorporation of ...
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...
Announced two abstracts across distinct tumor types were accepted for presentation at the American Association ...
Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in...
Announced the initiation of a metastatic colorectal cancer Phase 2 study that will be referred to as ...
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L...